WHO. Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization; 2021.

WHO. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization; 2021.

Lu PJ, Hung MC, Srivastav A, Grohskopf LA, Kobayashi M, Harris AM, et al. Surveillance of vaccination coverage among adult populations -United States, 2018. MMWR Surveill Summ. 2021;70(3):1–26.

Article  PubMed  PubMed Central  Google Scholar 

Weiser J, Perez A, Bradley H, King H, Shouse RL. Low prevalence of hepatitis B vaccination among patients receiving medical care for HIV infection in the United States, 2009 to 2012. Ann Intern Med. 2018;168(4):245–54.

Article  PubMed  Google Scholar 

Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, et al. Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis. J Viral Hepat. 2020;27(3):294–315.

Article  PubMed  Google Scholar 

Leumi S, Bigna JJ, Amougou MA, Ngouo A, Nyaga UF, Noubiap JJ. Global burden of hepatitis B infection in people living with human immunodeficiency virus: a systematic review and meta-analysis. Clin Infect Dis. 2020;71(11):2799–806.

Article  PubMed  Google Scholar 

Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT, Investigators HOSH. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996–2007. J Viral Hepat. 2010;17(12):879–86.

Article  CAS  PubMed  Google Scholar 

Hadler SC, Judson FN, O’Malley PM, Altman NL, Penley K, Buchbinder S, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis. 1991;163(3):454–9.

Article  CAS  PubMed  Google Scholar 

Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163(5):1138–40.

Article  CAS  PubMed  Google Scholar 

Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921–6.

Article  PubMed  Google Scholar 

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19(6):593–601.

Article  PubMed  Google Scholar 

Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24(3):211–7.

Article  CAS  PubMed  Google Scholar 

Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47(4):527–37.

Article  PubMed  Google Scholar 

Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis. 2012;55(4):507–13.

Article  PubMed  PubMed Central  Google Scholar 

Grant JL, Agaba P, Ugoagwu P, Muazu A, Okpokwu J, Akpa S, et al. Changes in liver stiffness after ART initiation in HIV-infected Nigerian adults with and without chronic HBV. J Antimicrob Chemother. 2019;74(7):2003–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vinikoor MJ, Sinkala E, Chilengi R, Mulenga LB, Chi BH, Zyambo Z, et al. Impact of antiretroviral therapy on liver fibrosis among human immunodeficiency virus-infected adults with and without HBV coinfection in Zambia. Clin Infect Dis. 2017;64(10):1343–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016;63(9):1160–7.

PubMed  PubMed Central  Google Scholar 

Farooq PD, Sherman KE. Hepatitis B vaccination and waning hepatitis B immunity in persons living with HIV. Curr HIV/AIDS Rep. 2019;16(5):395–403.

Article  PubMed  Google Scholar 

Nicolini LA, Magne F, Signori A, Di Biagio A, Sticchi L, Paganino C, et al. Hepatitis B virus vaccination in HIV: immunogenicity and persistence of seroprotection up to 7 years following a primary immunization course. AIDS Res Hum Retroviruses. 2018;34(11):922–8.

Article  CAS  PubMed  Google Scholar 

Lee JH, Hong S, Im JH, Lee JS, Baek JH, Kwon HY. Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. Vaccine. 2020;38(24):3995–4000.

Article  CAS  PubMed  Google Scholar 

Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477–83.

Article  PubMed  PubMed Central  Google Scholar 

Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B Virus Infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1–31.

Article  PubMed  PubMed Central  Google Scholar 

Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33; quiz CE1–4. Erratum in: MMWR Morb Mortal Wkly Rep. 2007 Oct 26;56(42):1114.

Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. pp. L1–L15. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection. Accessed 11/6/2022.

Tian Y, Hua W, Wu Y, Zhang T, Wang W, Wu H, et al. Immune response to hepatitis B virus vaccine among people living with HIV: a meta-analysis. Front Immunol. 2021;12:745541.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect. 1986;13(Suppl A):39–45.

Article  PubMed  Google Scholar 

Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998;15(1):1–8.

Article  CAS  PubMed  Google Scholar 

Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine. 2012;30(15):2556–63. This article describes the rate of seroprotection against HBV in healthy adults ages 18–55 following vaccination with Heplisav-B.

Article  CAS  PubMed  Google Scholar 

Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 2013;31(46):5300–5. This article describes the rate of seroprotection against HBV in healthy adults ages 40–70 following vaccination with Heplisav-B.

Article  CAS  PubMed  Google Scholar 

Marks KM, Kang M, Umbleja T, Avihingsanon A, Sugandhavesa P, Cox AL, et al. Immunogenicity and safety of hepatitis B virus (HBV) vaccine with a toll-like receptor 9 agonist adjuvant in HBV vaccine-naïve people with human immunodeficiency virus. Clin Infect Dis. 2023;77(3):414–8. https://doi.org/10.1093/cid/ciad201. This article describes the seroprotection rates among PLWH following 3 doses of Heplisav-B.

Schnittman SR, Zepf R, Cocohoba J, Sears D. Brief report: Heplisav-B Seroprotection in people with HIV: a single-center experience. J Acquir Immune Defic Syndr. 2021;86(4):445–9.

Article  PubMed  Google Scholar 

Reilly-Evans B, Dudzik B, Costlow DJ, Hartmann C, Khalsa AM, Kassis C, et al. Observational study evaluating the seroprotection of HepB-alum vaccine and HepB-CpG vaccine in people with HIV. Open Forum Infect Dis. 2023;10(6):ofad267.

Article  PubMed  PubMed Central  Google Scholar 

Vesikari T, Langley JM, Segall N, Ward BJ, Cooper C, Poliquin G, et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2021;21(9):1271–81. This study describes HBV seroprotection among HIV-negative adults following three doses of PreHevbrio.

Article  CAS  PubMed  Google Scholar 

Vesikari T, Finn A, van Damme P, Leroux-Roels I, Leroux-Roels G, Segall N, et al. Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial. JAMA Netw Open. 2021;4(10):e2128652.

Article  PubMed  PubMed Central  Google Scholar 

Alon D, Stein GY, Hadas-Golan V, Tau L, Brosh T, Turner D. Immunogenicity of Sci-B-Vac (a third-generation hepatitis B vaccine) in HIV-positive adults. Isr Med Assoc J. 2017;19(3):143–6.

PubMed  Google Scholar 

Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS. 2009;20(9):595–600.

Article  CAS  PubMed  Google Scholar 

Seremba E, Ocama P, Ssekitoleko R, Mayanja-Kizza H, Adams SV, Orem J, et al. Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda. Vaccine. 2021;39(8):1265–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine. 2012;30(41):5973–7.

Article  CAS  PubMed